Epratuzumab: Difference between revisions
m Protected "Epratuzumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +) |
||
Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 39: | Line 39: | ||
{{humanizedmonoclonals}} | {{humanizedmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] |
Latest revision as of 02:20, 9 August 2012
WikiDoc Resources for Epratuzumab |
Articles |
---|
Most recent articles on Epratuzumab Most cited articles on Epratuzumab |
Media |
Powerpoint slides on Epratuzumab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Epratuzumab at Clinical Trials.gov Clinical Trials on Epratuzumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Epratuzumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Epratuzumab Discussion groups on Epratuzumab Patient Handouts on Epratuzumab Directions to Hospitals Treating Epratuzumab Risk calculators and risk factors for Epratuzumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Epratuzumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).
See also
Template:Humanizedmonoclonals Template:WH Template:WikiDoc Sources